Neu­ro­crine re­ports a sec­ond PhI­II suc­cess in con­gen­i­tal adren­al hy­per­pla­sia, this time in chil­dren

Neu­ro­crine Bio­sciences said its treat­ment for con­gen­i­tal adren­al hy­per­pla­sia (CAH) — a ge­net­ic dis­or­der that caus­es hor­mone im­bal­ance — helped re­duce the dai­ly dose of steroids that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER